221 related articles for article (PubMed ID: 10697615)
1. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
2. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
3. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
4. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
Schwarz-Roeger U; Petzoldt B; Waldschmidt R; Walker RP; Bauknecht T; Kiechle M
Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597
[TBL] [Abstract][Full Text] [Related]
5. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
6. UGP in urogenital disorders: Egyptian experience.
el-Ahmady O; Halim AB; Gad M; Walker R
Anticancer Res; 1996; 16(4B):2301-8. PubMed ID: 8694560
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)].
Radici E; Persiani P; Stroppa S; Lombardi PL; Torre GC
Minerva Ginecol; 1996; 48(1-2):5-9. PubMed ID: 8750482
[TBL] [Abstract][Full Text] [Related]
8. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
10. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
11. Following metastatic placental site trophoblastic tumor with urine beta-core fragment.
Rinne K; Shahabi S; Cole L
Gynecol Oncol; 1999 Aug; 74(2):302-3. PubMed ID: 10419751
[TBL] [Abstract][Full Text] [Related]
12. Urinary gonadotropin peptide in patients with cancer of digestive organs.
Motoo Y; Watanabe H; Yamaguchi Y; Mouri I; Fujii T; Yamakawa O; Satomura Y; Okai T; Sawabu N
Anticancer Res; 1996; 16(4A):2041-8. PubMed ID: 8712740
[TBL] [Abstract][Full Text] [Related]
13. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
14. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
15. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
17. [Use of biochemical markers to predict the outcome of pregnancies conceived by in vitro fertilization].
Hauzman E; Murber A; Fancsovits P; Papp Z; Urbancsek J
Orv Hetil; 2006 Jul; 147(30):1409-20. PubMed ID: 16977779
[TBL] [Abstract][Full Text] [Related]
18. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
19. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
20. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
